Camurus AB (publ) (CAMRF)
| Market Cap | 3.19B -9.9% |
| Revenue (ttm) | 235.39M +21.3% |
| Net Income | 71.68M +71.7% |
| EPS | 1.19 +70.3% |
| Shares Out | n/a |
| PE Ratio | 44.47 |
| Forward PE | 28.26 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 200 |
| Average Volume | 210 |
| Open | 63.30 |
| Previous Close | 55.00 |
| Day's Range | 63.30 - 63.30 |
| 52-Week Range | 52.31 - 71.07 |
| Beta | 0.50 |
| RSI | 50.59 |
| Earnings Date | Apr 29, 2026 |
About Camurus AB
Camurus AB (publ), a biopharmaceutical company, develops and commercializes medicines for severe and chronic diseases in Europe, Africa, the Middle East, North America, and Asia. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence and chronic pain; and Brixadi to treat opioid use disorder. It also provides CAM2038 for the treatment of chronic pain; CAM2029, which completed phase III clinical trials for the treatment of acromegaly, and phase III clinical trials to treat gastroenteropancreatic neuroendocri... [Read more]
Financial Performance
In 2025, Camurus AB's revenue was 2.27 billion, an increase of 21.30% compared to the previous year's 1.87 billion. Earnings were 735.57 million, an increase of 71.70%.
Financial numbers in SEK Financial StatementsNews
Camurus AB Reports Q1 2026 Earnings with Mixed Results
Camurus AB Reports Q1 2026 Earnings with Mixed Results
Camurus AB (CAMRF) Q1 2026 Earnings Call Highlights: Strong Revenue Growth Amidst Market Challenges
Camurus AB (CAMRF) Q1 2026 Earnings Call Highlights: Strong Revenue Growth Amidst Market Challenges
Q1 2026 Camurus AB Earnings Call Transcript
Q1 2026 Camurus AB Earnings Call Transcript
Camurus AB Earnings Call Transcript: Q1 2026
Q1 2026 results showed sequential revenue growth and strong profitability, with robust in-market demand for key products and a solid cash position. Full-year guidance was reaffirmed, with major milestones ahead including FDA decisions and pivotal study readouts.
Camurus AB Earnings Call Transcript: Q4 2025
2025 saw strong revenue and profit growth, driven by Brixadi royalties and Buvidal expansion, despite FX headwinds and a UK distribution change. Regulatory milestones included Oczyesa approval and launch, while R&D advanced with positive CAM2056 results. 2026 guidance anticipates continued double-digit growth and increased investment in U.S. operations.
Camurus announces FDA acceptance of NDA resubmission for Oclaiz
Camurus (CAMRF) announced that the U.S. Food and Drug Administration has accepted for review the company’s resubmission of the New Drug Application for Oclaiz, octreotide extended-release injection, f...
Camurus AB Transcript: Jefferies London Healthcare Conference 2025
The session highlighted strong clinical progress for once-monthly semaglutide and long-acting octreotide, robust commercial growth for opioid use disorder treatments, and a strategic partnership with Eli Lilly. Despite a 2025 outlook downgrade, profit guidance is maintained and future growth is expected from new launches and partnerships.
Camurus reports positive topline results for CAM2056, semaglutide monthly depot
CAM2056 showed weight and A1c reductions comparable to or exceeding those seen for weekly semaglutide (Wegovy®) Results include a 9.3% weight reduction with CAM2056 vs. 5.2% with weekly semaglutide at...
Camurus AB Earnings Call Transcript: Q3 2025
Q3 2025 saw strong profitability, 18% revenue growth year-on-year, and robust cash flow, but full-year revenue guidance was lowered due to U.S. and U.K. headwinds. Product launches and pipeline progress continued, with Oczyesa launched in Germany and Brixadi gaining U.S. market share.
Camurus AB Earnings Call Transcript: Q2 2025
Record Q2 revenues and profitability driven by Buvidal and Brixadi growth, EU approval of Oxyceisa, and a major licensing deal with Eli Lilly. Strong cash position and maintained guidance, with further growth expected in H2 as funding and access improve.
Camurus upgraded to Buy from Hold at DNB Carnegie
DNB Carnegie analyst Erik Hultgard upgraded Camurus (CAMRF) to Buy from Hold with an SEK 800 price target
Camurus' POSITANO study shows treatment effects with CAM2029 in polycystic liver disease patients
CAM2029 reduces liver and cyst volume growth compared to placebo Well tolerated with no new or unexpected safety findings A follow-up Phase 3 study will be discussed with regulatory authorities LUND,...
Camurus AB Transcript: Jefferies Global Healthcare Conference 2025
A major partnership with Eli Lilly validates the FluidCrystal platform, while Brixadi and Buvidal continue to expand globally despite temporary Medicaid headwinds. CAM2029 and CAM2056 advance in late-stage trials, supporting a confident outlook for 40%-50% revenue growth in 2024.
Camurus, Lilly enter collaboration pact for long-acting FluidCrystal incretins
Camurus (CAMRF) and Eli Lilly (LLY) have entered a collaboration and license agreement, granting Lilly exclusive, worldwide rights to the research, development, manufacture, and commercialization of l...
Camurus and Lilly enter collaboration and license agreement for long-acting FluidCrystal® incretins
Partnership focused on development of long-acting therapies based on Camurus' FluidCrystal® technology and Eli Lilly's proprietary drug compounds Camurus eligible to receive up to $870 million in pote...
Camurus AB Earnings Call Transcript: Q1 2025
Q1 2025 saw record profitability, 43% revenue growth, and strong Buvidal expansion in Europe and Australia. Brixadi U.S. royalties surged 185% year-over-year despite a 13% market decline, and regulatory progress for CAM2029 in acromegaly continues in the EU and U.S.
CHMP recommends approval of Oczyesa® for treatment of acromegaly in the EU
LUND, Sweden , April 25, 2025 /PRNewswire/ -- Camurus (NASDAQ STO: CAMX) today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positi...
Camurus AB Earnings Call Transcript: Q4 2024
Strong revenue and profit growth in 2024 driven by Buvidal and Brixadi, with robust cash position and no debt. Regulatory progress and new launches are expected to fuel 2025 growth, while manufacturing expansion and R&D investments support long-term targets.
Camurus AB Transcript: Jefferies London Healthcare Conference 2024
Strong progress toward 2027 targets with raised guidance and expanding product uptake in key markets. Regulatory milestones for CAM2029 and new pipeline advances are expected in 2025, while commercial opportunities in opioid use disorder and rare diseases remain robust.
Camurus AB Earnings Call Transcript: Q3 2024
Q3 saw revenue rise to SEK 480 million and profit before tax up 125% year-over-year, driven by strong Buvidal and Brixadi sales. Guidance for 2024 was raised, with robust cash reserves and continued R&D progress, despite regulatory delays for CAM2029.
US FDA declines to approve Camurus' rare hormone disorder drug
The U.S. Food and Drug Administration has declined to approve Camurus' drug for the treatment of a rare hormonal disorder due to deficiencies at a third-party manufacturing facility, the Swedish drugm...
Camurus AB Earnings Call Transcript: Q2 2024
Q2 2024 saw 46% year-over-year revenue growth (excluding one-time items), strong Buvidal and Brixadi sales, and a gross margin of 92.9%. R&D and pipeline advances continued, with guidance reiterated for the year.
New publication shows effectiveness data for weekly and monthly buprenorphine injections in treating opioid dependence in individuals using fentanyl
LUND, Sweden , June 25, 2024 /PRNewswire/ -- Camurus (NASDAQ STO: CAMX) today announced the publication in JAMA Network Open of a new post hoc analysis from a 24-week randomized, double-blind, Phase 3...